Luscii – An OMRON Healthcare Service

Background

Luscii Healthtech B.V., established in January 2019, is a Dutch medical software company specializing in remote patient monitoring and virtual ward solutions. The company's mission is to "create space for care" by enabling healthcare professionals to monitor and guide patients remotely, thereby reducing unnecessary hospital visits and admissions. Luscii's platform is utilized across various healthcare settings, including hospitals, general practitioners, and community care centers, aiming to enhance patient outcomes and operational efficiency.

Key Strategic Focus

Luscii's strategic focus centers on:

Remote Patient Monitoring: Providing a customizable platform that supports over 150 disease-specific care pathways, including chronic conditions like heart failure, COPD, and hypertension.

Virtual Wards: Facilitating the creation of virtual hospital wards to manage patients at home, reducing the burden on physical healthcare facilities.

Integrated Care Networks: Seamlessly connecting various healthcare stakeholders, such as general practitioners, hospitals, and community care centers, to ensure cohesive patient care.

Technological Integration: Incorporating advanced technologies, including AI-driven clinical engines and interoperability with existing electronic patient records (EPRs), to streamline healthcare processes.

Financials and Funding

Luscii began as an independent company in 2019 with a strategic partnership with OMRON Healthcare, which held a minority stake. In April 2024, OMRON Healthcare acquired all shares of Luscii, integrating it fully into its operations. This acquisition aims to advance and scale remote patient monitoring services globally, aligning with OMRON's "Going for Zero" vision to eliminate heart attacks and strokes.

Pipeline Development

Luscii has developed and implemented over 350 digital care transformation pathways since 2014, covering a wide range of conditions. Notable programs include:

Heart Failure Program: Achieved an 81% reduction in unplanned admissions and a 65% decrease in A&E visits at Imperial College Healthcare NHS Trust.

COPD Program: Realized a 58% reduction in emergency admissions and a 34% decrease in primary care usage with the All Together Better Alliance Sunderland.

These programs are continuously refined based on clinical feedback and patient outcomes, with ongoing efforts to expand into new therapeutic areas and geographies.

Technological Platform and Innovation

Luscii's platform is distinguished by:

Proprietary Technologies: The Luscii Clinical Engine, a CE-marked Class IIa Medical Device, utilizes AI algorithms to monitor patient vitals and detect abnormalities, enabling timely interventions.

Customizable Care Pathways: Healthcare professionals can create and customize care pathways or select from a library of over 150 pre-existing programs developed in collaboration with clinical teams.

Interoperability: The platform integrates seamlessly with existing electronic patient records (EPRs), ensuring efficient data flow and reducing administrative burdens.

AI-Driven Workflow Optimization: Advanced algorithms analyze patient data to prioritize care needs, allowing clinicians to focus on patients requiring immediate attention.

Leadership Team

Luscii's leadership comprises:

Prof. Daan Dohmen, PhD: Founder and CEO. With a background in healthcare innovation, Prof. Dohmen has been instrumental in developing Luscii's vision and strategic direction.

Dr. Joris Janssen: Co-founder. Dr. Janssen has played a pivotal role in the technological development and implementation of Luscii's platform.

Ronald Scheffer: Co-founder. Scheffer has contributed significantly to the operational and business development aspects of Luscii.

Erik Kaufman: Co-founder. Kaufman has been involved in shaping Luscii's organizational culture and strategic partnerships.

Leadership Changes

In April 2024, following the acquisition by OMRON Healthcare, Luscii's founders, including Prof. Daan Dohmen, Dr. Joris Janssen, Ronald Scheffer, and Erik Kaufman, continued their roles within the company, ensuring continuity in leadership and strategic direction.

Competitor Profile

Market Insights and Dynamics

The remote patient monitoring (RPM) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases, advancements in digital health technologies, and the need for cost-effective healthcare solutions. The COVID-19 pandemic has further accelerated the adoption of RPM solutions, highlighting their importance in managing patient care remotely.

Competitor Analysis

Key competitors in the RPM space include:

AliveCor: Specializes in personal electrocardiogram (ECG) technology, offering devices that enable patients to monitor heart rhythms at home.

EXI: Provides digital therapeutic solutions focused on personalized exercise prescriptions for patients with long-term health conditions.

Other RPM Providers: Various companies offer RPM solutions with varying degrees of integration, customization, and technological sophistication.

Strategic Collaborations and Partnerships

Luscii has established several strategic partnerships to enhance its service offerings:

AliveCor Collaboration: In June 2023, Luscii partnered with AliveCor to integrate advanced 6-lead ECG technology into its platform, creating the world's first "virtual heart clinic in a box."

EXI Partnership: In April 2023, Luscii collaborated with EXI to incorporate personalized, intensity-based physical activity prescriptions into its care pathways, initially focusing on cardiology and COPD programs.

OMRON Healthcare Acquisition: In April 2024, OMRON Healthcare acquired Luscii, aiming to scale and innovate remote patient monitoring services globally.

Operational Insights

Luscii's operational strategy emphasizes:

Customization and Flexibility: Offering a platform that allows healthcare providers to create and adapt care pathways to meet specific patient needs.